Neovacs buys Interferon Alpha manufacturing licence from Argentinian Amegabiotech

interferon-alfa

Image: Amega

Neovacs, a biotechnology company focused on active immunotherapies for the treatment of autoimmune diseases, has agreed with the Argentinean company Amegabiotech to acquire its Interferon Alpha (IFNalpha) manufacturing license.

Amegabiotech is a global producer of IFNalpha protein and a long term supplier of Neovacs, particularly for its on-going Phase IIb study of IFNalpha Kinoid in Lupus.

IFNalpha is a key component of Neovacs` lead therapeutic candidate, IFNalpha Kinoid, which is composed of inactivated IFNalpha coupled with a carrier protein, keyhole limpet hemocyanin.

Miguel Sieler, CEO of Neovacs, commented: “With this agreement, the company has reinforced its ability to maintain control of its technology, quality control, manufacturing and costs, which is key to our overall growth strategy as we continue advancing the clinical development of our lead candidate IFNalpha Kinoid. With greater control over our Kinoid technology, we can drive optimization of manufacturing costs and more effectively support the potential commercialization of IFNalpha Kinoid for the treatment of lupus, a complex autoimmune disease where medical needs are urgent and unmet today.”

Leave a Reply

Please log in using one of these methods to post your comment:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s